Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/24/20
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 09/02/20
End: 06/22/23
Due: 06/22/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | NCT04115163 | Anne Noonan | user2@example.com | None | 2020-06-24 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | NCT04164069 | Anne Noonan | user2@example.com | None | 2020-09-02 | 2023-06-22 | 2024-06-22 | - | - | 2025-07-14 |